Damora Therapeutics (formerly Galecto) Announces Name Change, Pipeline Milestones, and Strong Financial Position
Damora Therapeutics (formerly Galecto) Announces Name Change, Pipeline Milestones, and Strong Financial Position
Key Points for Investors
- Name Change & Rebranding: Galecto, Inc. has officially changed its name to Damora Therapeutics, Inc. The company will begin trading on the Nasdaq under the new symbol DMRA effective March 10, 2026.
- Strategic Acquisition & Capital Infusion: The name change follows the completion of Galecto’s acquisition of privately held Damora and a concurrent private investment of approximately \$285 million in November 2025. Additionally, Damora raised gross proceeds of about \$316 million from a public offering in February 2026, bringing its total cash position to approximately \$535 million as of February 28, 2026.
- Robust Financial Runway: The company anticipates this cash will fund operations into Phase 3 development for its lead asset DMR-001.
- Pipeline Progress: Damora is focused on developing best-in-class monoclonal antibody therapies targeting mutant calreticulin (mutCALR) in essential thrombocythemia (ET) and myelofibrosis (MF), rare chronic blood cancers with high unmet medical need.
- Clinical Development Timelines:
- IND or CTA submission for lead candidate DMR-001 targeting mutCALR-driven ET and MF expected in mid-2026.
- IND or CTA for DMR-002 planned for the second half of 2026.
- IND or CTA for DMR-003 scheduled for 2027.
- Two clinical proof-of-concept datasets for DMR-001 anticipated beginning mid-2027.
- Product Differentiation: DMR-001 is an investigational monoclonal antibody therapy with preclinical data supporting potent inhibition of both Type 1 and Type 2 mutCALR and an extended half-life, potentially enabling convenient and infrequent subcutaneous dosing.
- Market Opportunity: Approximately 42,000 patients in the US live with mutCALR-driven myeloproliferative neoplasms (MPNs), representing a significant addressable market where no current therapies target the underlying disease cause.
- Leadership and Execution: Damora boasts an experienced board and executive leadership team with proven clinical and commercial success, positioning the company for rapid advancement of its pipeline.
Detailed Article
BOSTON, March 9, 2026 – In a major corporate update, Galecto, Inc. has completed its transition to Damora Therapeutics, Inc., heralding a new era for the company’s focus on hematologic disorders. Investors should note that Damora will begin trading under the new Nasdaq ticker DMRA starting March 10, 2026, a move that may attract renewed attention and liquidity to the stock.
The rebranding and strategic repositioning are anchored by the recent acquisition of privately held Damora and a substantial concurrent private investment of \$285 million in November 2025. This was followed by a successful public offering that raised an additional \$316 million in February 2026. As of February 28, 2026, Damora has a robust cash position of approximately \$535 million, providing a financial runway into Phase 3 development for its lead asset, DMR-001. This financial strength is a critical factor for shareholders, as it reduces near-term dilution risk and supports aggressive pipeline development.
Damora’s pipeline is centered on innovative, disease-modifying biologics for patients with mutCALR-driven myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET) and myelofibrosis (MF). These rare blood cancers are characterized by abnormal blood cell production in the bone marrow. Current data indicate that mutCALR is a driver of disease progression in 25% of ET and 35% of MF cases, affecting an estimated 42,000 patients in the US alone.
The company’s lead candidate, DMR-001, is a monoclonal antibody designed to inhibit both Type 1 and Type 2 mutCALR, with preclinical studies suggesting best-in-class potential. Its extended half-life may allow for convenient, infrequent subcutaneous dosing, a differentiator versus existing therapies. Damora’s pipeline also includes DMR-002 and DMR-003, offering portfolio flexibility to address the full spectrum of mutCALR-driven MPNs.
Key upcoming milestones for Damora include:
- Submission of an investigational new drug (IND) or clinical trial application (CTA) for DMR-001 in mid-2026.
- IND or CTA submission for DMR-002 in the second half of 2026.
- IND or CTA submission for DMR-003 in 2027.
- Presentation of two clinical proof-of-concept datasets for DMR-001 beginning mid-2027.
These milestones represent critical inflection points that could significantly impact share price, especially as clinical data emerges.
Damora’s leadership team, including Chief Operating Officer Sherwin Sattarzadeh, emphasizes the company’s commitment to scaling clinical development and rapidly advancing DMR-001 toward registration. With a strong operational foundation and leadership with proven track records, Damora is well-positioned to execute on its ambitious pipeline.
Forward-Looking Statements & Risks: Investors are reminded that statements about future milestones, clinical data, and financial runway are forward-looking and subject to risks, uncertainties, and assumptions. These include, but are not limited to, clinical trial success, regulatory approval, and market dynamics. Any delays or negative outcomes in clinical development could impact share value.
For further information, investors are encouraged to visit www.damoratx.com or follow Damora on LinkedIn. Media and investor contacts are provided below for additional inquiries.
Contacts
Disclaimer
This article contains forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied due to factors such as clinical trial outcomes, regulatory approvals, and market conditions. The information provided is for informational purposes only and should not be construed as investment advice. Investors should conduct their own due diligence and consult with financial advisors before making any investment decisions.
View Galecto, Inc. Historical chart here
